1-19 of 19
Authors: D Thomas
Sort by
Journal Article
P0869 Model-informed dosage de-escalation of infliximab in patients with inflammatory bowel diseases
Z Wang and others
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i1652–i1653, https://doi.org/10.1093/ecco-jcc/jjae190.1043
Published: 22 January 2025
Journal Article
P0865 Impact of assay on the predictive performance of model-informed precision dosing of ustekinumab in patients with Crohn’s disease
W Zhang and others
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i1645–i1646, https://doi.org/10.1093/ecco-jcc/jjae190.1039
Published: 22 January 2025
Journal Article
P1041 Coconut water modulates dietary potassium and gut microbiome to induce remission in ulcerative colitis: randomized controlled trial
S Kedia and others
Journal of Crohn's and Colitis, Volume 18, Issue Supplement_1, January 2024, Page i1877, https://doi.org/10.1093/ecco-jcc/jjad212.1171
Published: 24 January 2024
Journal Article
P701 A time-to-event model relating infliximab trough concentrations to the risk of relapse after extending the infusion interval
W Kantasiripitak and others
Journal of Crohn's and Colitis, Volume 17, Issue Supplement_1, February 2023, Pages i833–i834, https://doi.org/10.1093/ecco-jcc/jjac190.0831
Published: 30 January 2023
Journal Article
P531 A model-based tool for guiding infliximab induction dosing to maximise long-term deep remission in children with inflammatory bowel diseases
W Kantasiripitak and others
Journal of Crohn's and Colitis, Volume 17, Issue Supplement_1, February 2023, Pages i659–i661, https://doi.org/10.1093/ecco-jcc/jjac190.0661
Published: 30 January 2023
Journal Article
P533 Predictors of sustained remission after infliximab de-escalation in patients with inflammatory bowel diseases
W Kantasiripitak and others
Journal of Crohn's and Colitis, Volume 16, Issue Supplement_1, January 2022, Pages i485–i486, https://doi.org/10.1093/ecco-jcc/jjab232.660
Published: 21 January 2022
Journal Article
P442 Real-world endoscopic and histologic outcomes are linked to ustekinumab exposure in Ulcerative Colitis
D Alsoud and others
Journal of Crohn's and Colitis, Volume 16, Issue Supplement_1, January 2022, Page i424, https://doi.org/10.1093/ecco-jcc/jjab232.569
Published: 21 January 2022
Journal Article
P333 Precise and unbiased infliximab dosing in patients with inflammatory bowel diseases using a multi-model averaging approach
W Kantasiripitak and others
Journal of Crohn's and Colitis, Volume 16, Issue Supplement_1, January 2022, Pages i350–i351, https://doi.org/10.1093/ecco-jcc/jjab232.460
Published: 21 January 2022
Journal Article
P582 Insights on the sphingolipid profile in patients with short bowel syndrome and consecutive intestinal failure
A Kubesch and others
Journal of Crohn's and Colitis, Volume 15, Issue Supplement_1, May 2021, Page S536, https://doi.org/10.1093/ecco-jcc/jjab076.703
Published: 27 May 2021
Journal Article
P405 Development and validation of a rapid immunoassay for monitoring of ustekinumab concentrations in Inflammatory Bowel Disease patients
D Thomas and others
Journal of Crohn's and Colitis, Volume 15, Issue Supplement_1, May 2021, Page S412, https://doi.org/10.1093/ecco-jcc/jjab076.529
Published: 27 May 2021
Journal Article
P304 Rational infliximab induction dosing to achieve long-term deep remission in children with Inflammatory Bowel Diseases
W Kantasiripitak and others
Journal of Crohn's and Colitis, Volume 15, Issue Supplement_1, May 2021, Pages S332–S333, https://doi.org/10.1093/ecco-jcc/jjab076.428
Published: 27 May 2021
Journal Article
P311 Intensive dried blood spot sampling shows a higher drug exposure throughout the first 24 weeks of therapy in ustekinumab-treated Crohn’s disease patients achieving endoscopic remission
N Van den Berghe and others
Journal of Crohn's and Colitis, Volume 15, Issue Supplement_1, May 2021, Pages S338–S339, https://doi.org/10.1093/ecco-jcc/jjab076.435
Published: 27 May 2021
Journal Article
P346 Single-centre experience of ustekinumab: Therapeutic drug monitoring in Crohn’s disease patients
C Liefferinckx and others
Journal of Crohn's and Colitis, Volume 14, Issue Supplement_1, January 2020, Pages S331–S333, https://doi.org/10.1093/ecco-jcc/jjz203.475
Published: 15 January 2020
Journal Article
P601 Development and validation of dried blood spot sampling as a tool to identify the best time point to measure predictive ustekinumab serum concentrations in patients with Crohn’s disease
N Van den Berghe and others
Journal of Crohn's and Colitis, Volume 14, Issue Supplement_1, January 2020, Page S502, https://doi.org/10.1093/ecco-jcc/jjz203.729
Published: 15 January 2020
Journal Article
P464 Vedolizumab concentrations in colonic mucosal tissue of ulcerative colitis patients inversely correlate with the severity of inflammation
N Van den Berghe and others
Journal of Crohn's and Colitis, Volume 14, Issue Supplement_1, January 2020, Pages S411–S412, https://doi.org/10.1093/ecco-jcc/jjz203.593
Published: 15 January 2020
Journal Article
P542 The effect of age on infliximab pharmacokinetics in patients with inflammatory bowel disease
W Kantasiripitak and others
Journal of Crohn's and Colitis, Volume 14, Issue Supplement_1, January 2020, Pages S462–S463, https://doi.org/10.1093/ecco-jcc/jjz203.670
Published: 15 January 2020
Journal Article
P362 Prospective study of phArmaCokinetics of InFliximab during induction in patients with Crohn’s disease and ulcerative colitis (PACIFIC)
C Liefferinckx and others
Journal of Crohn's and Colitis, Volume 14, Issue Supplement_1, January 2020, Pages S343–S344, https://doi.org/10.1093/ecco-jcc/jjz203.491
Published: 15 January 2020
Journal Article
P641 An increased baseline mucosal TNF burden linked to adalimumab non-response: opportunities for therapeutic drug monitoring
B Verstockt and others
Journal of Crohn's and Colitis, Volume 14, Issue Supplement_1, January 2020, Pages S531–S532, https://doi.org/10.1093/ecco-jcc/jjz203.769
Published: 15 January 2020
Journal Article
P075 Inflammation-induced cancer vs. cancer-induced inflammation is dependent on S1P lyase
Get access
A Schwiebs and others
Journal of Crohn's and Colitis, Volume 12, Issue supplement_1, February 2018, Page S130, https://doi.org/10.1093/ecco-jcc/jjx180.202
Published: 16 January 2018
Advertisement intended for healthcare professionals
Advertisement intended for healthcare professionals